These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 1481055

  • 21. Some haemorheological factors and transcutaneous PO2 in patients with a peripheral arterial occlusive disease after treatment with naftidrofuryl.
    Krupiński K, Bielawiec M, Szpak A, Płonowski A.
    Mater Med Pol; 1994; 26(1):17-20. PubMed ID: 7857406
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic efficacy of intravenously applied prostaglandin E1.
    Scheffler P, de la Hamette D, Leipnitz G.
    Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Usefulness of transcutaneous oximetry in detection of diabetic microangiopathy in lower limbs].
    Wróblewski T, Starzyńska R.
    Pol Tyg Lek; 1989; 49(16-17):376-8. PubMed ID: 7708557
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation.
    Caspary L, Creutzig A, Alexander K.
    Eur J Clin Pharmacol; 1991; 41(2):131-6. PubMed ID: 1720738
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Intra-arterial administration of prostaglandin E1 in occlusive arterial diseases].
    Davidović L, Vranes M, Cernak I, Kostić D, Lovrić A, Sagić D, Lotina S.
    Srp Arh Celok Lek; 1992; 120(1-2):9-14. PubMed ID: 1641706
    [Abstract] [Full Text] [Related]

  • 29. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome.
    Vincent JL, Brase R, Santman F, Suter PM, McLuckie A, Dhainaut JF, Park Y, Karmel J.
    Intensive Care Med; 2001 Oct; 27(10):1578-83. PubMed ID: 11685297
    [Abstract] [Full Text] [Related]

  • 30. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
    Wutte M, Hülsmann M, Berger R, Rödler S, Frey B, Stanek B, Pacher R.
    Wien Klin Wochenschr; 1998 Jul 31; 110(13-14):473-8. PubMed ID: 9746960
    [Abstract] [Full Text] [Related]

  • 31. [Transcutaneous oxygen pressure (TcPO2): advantages and limitations].
    Got I.
    Diabetes Metab; 1998 Sep 31; 24(4):379-84. PubMed ID: 9805653
    [Abstract] [Full Text] [Related]

  • 32. Intravenous prostavasin--therapy in peripheral arterial occlusive disease in Fontaine's stages III and IV. Early and late results of a screening study.
    Heidrich H, Meuche C, Ranft J, Rummel S, Peters A.
    Prog Clin Biol Res; 1989 Sep 31; 301():411-6. PubMed ID: 2678131
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
    Fitscha P, Simmet T, Peskar BA, Reuter H, Sinzinger H, Rogatti W, Tilsner V.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):477-81. PubMed ID: 3062905
    [Abstract] [Full Text] [Related]

  • 35. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
    Sinzinger H, Rogatti W.
    Wien Klin Wochenschr; 1991 Jul 15; 103(18):558-65. PubMed ID: 1750223
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.